Due to the COVID 19 epidemic, orders may be processed with a slight delay


Need help?
Need help?

In Stock

Opana (Oxymorphone) 40mg



Brand Name: Opana, Opana ER
Generic Name: Oxymorphone
Drug Class: Opioid Analgesics

Oxymorphone is a narcotic pain reliever used to treat moderate to severe pain. The extended-release form is for around-the-clock treatment of pain.

Oxymorphone is available under the following different brand names: Opana, and Opana ER.

Dosage Forms and Strengths
Injectable solution: Schedule II

1 mg/mL
Tablet: Schedule II

5 mg
10 mg
Tablet, extended release: Schedule II

5 mg
7.5 mg
10 mg
15 mg
20 mg
30 mg
40 mg
Tablet, extended release: abuse deterrent Schedule II

5 mg
7.5 mg
10 mg
15 mg
20 mg
30 mg
40 mg
Dosage Considerations – Should be Given as Follows:
Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death

Assess each patient’s risk prior to prescribing and monitor all patients regularly for the development of these behaviors or conditions

Preoperative Anesthesia/Analgesia

Also effective for relief of anxiety in patients with shortness of breath (dyspnea) associated with pulmonary edema secondary to acute left ventricular dysfunction

1-1.5 mg intramuscularly/subcutaneously (IM/SC) every 4-6 hours as needed
Analgesia during labor: 0.5-1 mg IM
Intravenously (IV): 0.5 mg, increased as needed
Moderate-to-Severe Pain


Immediate-release tablets indicated for acute moderate-to-severe pain where opioid use is appropriate
Opioid-naive patients (immediate-release): 10-20 mg orally every 4-6 hours as needed initially, then titrated as warranted (may start with 5-mg increments)
Conversion from intravenous (IV) oxymorphone to oral: The absolute bioavailability of orally is approximately 10%, therefore conversion from 1 mg IV every 4-6 hours is equipotent to 10 mg orally every 4-6 hours
Elderly patients or those with renal or hepatic impairment: 5 mg orally every 4-6 hours initially
Chronic Severe Pain

Extended-release is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Opioid-naive patients (extended-release): 5 mg orally every 12 hours initially, then titrated in increments of 5-10 mg every 12 hours every 3-7 days to level that provides adequate analgesia and minimizes side effects

Conversion from intravenous (IV) oxymorphone to extended-release oral: The absolute oral bioavailability of Opana ER is approximately 10%, therefore conversion from 1 mg IV every 6 hours (4 mg/day) is equipotent to 20 mg orally every 12 hours (40 mg/day)

Conversion from orally opioids to Opana ER: See prescribing information

Opioid-tolerant definition

Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression
Patients who are opioid tolerant are those receiving, for 1 week or longer, at least 60 mg/day orally morphine, 25 mcg/hour transdermal fentanyl, 30 mg/day orally oxycodone, 8 mg/day orally hydromorphone, 25 mg/day orally oxymorphone, or an equianalgesic dose of another opioid


50 Tablets, 100 Tablets, 250 Tablets, 500 Tablets


Es gibt noch keine Bewertungen.

Write a review

Deine E-Mail-Adresse wird nicht veröffentlicht.

Back to Top
Select your currency
Product has been added to your cart